Based on these results showing that 36.9% of PD1+ CD8 T cells (cluster 4) expressed the highest levels of LAG3, but were negative for TIM3 and had low levels of TIGIT, while the most exhausted CD8 T cells in cluster 1 only represented 11% of the PD1+ CD8 T cells, we reasoned that targeting PD1 and LAG3 could enhance tumor rejection. This evidence concerns the gene LAG3 and neoplasm.